Formulating Relief for RA & ITP

PRTX-100 is positioned to address a major unmet need in the autoimmune sector with Rheumatoid Arthritis (RA) and Immune Thrombocytopenia (ITP)

Learn More

About Protalex

Protalex is a biotechnology company developing a new class of drugs with the potential to revolutionize the treatment of autoimmune diseases.

Autoimmune Diseases

Today in the US, millions of individuals suffer from autoimmune diseases with Rheumatoid Arthritis and Immune Thrombocytopenia representing both large and niche markets.

Leadership Team

Protalex has an Experienced Management with committed support from an expert Scientific Advisory Board

Corporate Presentation May 2018 Download
Product Pipeline
Protalex, Inc. Pipeline
Stock Info
Market Cap
Sign Up for Email Alerts Be the first to receive breaking news Sign Up